Basic Information
Vyxeos liposomal (previously Vyxeos)
Regulatory Information
EMEA/H/C/004282
August 23, 2018
April 26, 2018
10
May 24, 2024
Company Information
Ireland
Fifth Floor Waterloo Exchange Waterloo Road D04 E5W7 Dublin 4
JAZZ PHARMACEUTICALS IRELAND LIMITED
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Overview Summary
Vyxeos liposomal is a cancer medicine used to treat adults with newly diagnosed acute myeloid leukaemia, a cancer of white blood cells. It is used when the leukaemia was caused by previous treatments (e.g. for other cancers) or is associated with certain changes in the bone marrow known as myelodysplasia. The active substances in Vyxeos liposomal are daunorubicin and cytarabine.